Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113300925 | 11330092 | 5 | F | 201303 | 20160727 | 20150803 | 20160727 | EXP | JP-PFIZER INC-2015253577 | PFIZER | 32.00 | YR | F | Y | 0.00000 | 20160727 | PH | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113300925 | 11330092 | 1 | PS | LYRICA | PREGABALIN | 1 | Oral | 75 MG, 1X/DAY BEFORE BEDTIME | Y | 21446 | 75 | MG | CAPSULE, HARD | QD | |||||
| 113300925 | 11330092 | 2 | SS | LYRICA | PREGABALIN | 1 | Oral | 75 MG, 2X/DAY | Y | 21446 | 75 | MG | CAPSULE, HARD | BID | |||||
| 113300925 | 11330092 | 3 | SS | LYRICA | PREGABALIN | 1 | Oral | 150 MG, 2X/DAY | Y | 21446 | 150 | MG | CAPSULE, HARD | BID | |||||
| 113300925 | 11330092 | 4 | SS | LYRICA | PREGABALIN | 1 | Oral | 75 MG, 2X/DAY | Y | 21446 | 75 | MG | CAPSULE, HARD | BID | |||||
| 113300925 | 11330092 | 5 | SS | LYRICA | PREGABALIN | 1 | Oral | 150 MG, 2X/DAY | Y | 21446 | 150 | MG | CAPSULE, HARD | BID | |||||
| 113300925 | 11330092 | 6 | C | DEPAS | ETIZOLAM | 1 | 0 | ||||||||||||
| 113300925 | 11330092 | 7 | C | GASLON | IRSOGLADINE MALEATE | 1 | 0 | ||||||||||||
| 113300925 | 11330092 | 8 | C | NEUROTROPIN | NEUROTROPIN | 1 | 0 | ||||||||||||
| 113300925 | 11330092 | 9 | C | DUROTEP MT | FENTANYL | 1 | 2.1 MG, UNK | 0 | 2.1 | MG | |||||||||
| 113300925 | 11330092 | 10 | C | DUROTEP MT | FENTANYL | 1 | 4.2 MG, UNK | 0 | 4.2 | MG | |||||||||
| 113300925 | 11330092 | 11 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113300925 | 11330092 | 1 | Complex regional pain syndrome |
| 113300925 | 11330092 | 2 | Pain |
| 113300925 | 11330092 | 3 | Oedema |
| 113300925 | 11330092 | 4 | Feeling hot |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113300925 | 11330092 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113300925 | 11330092 | Drug eruption | |
| 113300925 | 11330092 | Drug tolerance | |
| 113300925 | 11330092 | Menstrual disorder | |
| 113300925 | 11330092 | Product use issue | |
| 113300925 | 11330092 | Rotator cuff syndrome | |
| 113300925 | 11330092 | Visual acuity reduced | |
| 113300925 | 11330092 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113300925 | 11330092 | 1 | 201303 | 0 | ||
| 113300925 | 11330092 | 2 | 201304 | 0 | ||
| 113300925 | 11330092 | 3 | 201305 | 0 | ||
| 113300925 | 11330092 | 4 | 201307 | 201307 | 0 | |
| 113300925 | 11330092 | 5 | 201307 | 0 | ||
| 113300925 | 11330092 | 9 | 201402 | 0 |